Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK
Rui Cai,1 Alan A Martin,2 Yuchen Ge,3 Nancy A Risebrough,3 Katrin Haeussler,4 Christopher Compton,5 David MG Halpin,6 Afisi S Ismaila7,8 1ICON Health Economics, ICON plc, Amsterdam, the Netherlands; 2Value Evidence and Outcomes, GSK, London, UK; 3ICON Health Economics, ICON plc, Toronto, ON, Canada;...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-08-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/economic-analysis-of-new-single-inhaler-triple-therapies-in-patients-w-peer-reviewed-fulltext-article-COPD |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849395250546606080 |
|---|---|
| author | Cai R Martin AA Ge Y Risebrough NA Haeussler K Compton C Halpin DM Ismaila AS |
| author_facet | Cai R Martin AA Ge Y Risebrough NA Haeussler K Compton C Halpin DM Ismaila AS |
| author_sort | Cai R |
| collection | DOAJ |
| description | Rui Cai,1 Alan A Martin,2 Yuchen Ge,3 Nancy A Risebrough,3 Katrin Haeussler,4 Christopher Compton,5 David MG Halpin,6 Afisi S Ismaila7,8 1ICON Health Economics, ICON plc, Amsterdam, the Netherlands; 2Value Evidence and Outcomes, GSK, London, UK; 3ICON Health Economics, ICON plc, Toronto, ON, Canada; 4ICON Health Economics, ICON plc, Munich, Germany; 5Global Medical, GSK, London, UK; 6University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK; 7Value Evidence and Outcomes, GSK, Collegeville, PA, USA; 8Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence: Afisi S Ismaila, Value Evidence and Outcomes, GSK, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA, Tel +19193158229, Email afisi.s.ismaila@gsk.comPurpose: Chronic obstructive pulmonary disease (COPD) is associated with a substantial economic burden in the UK. Although previous analyses have compared the cost-effectiveness of single-inhaler triple therapy (SITT) versus dual therapy or multiple-inhaler triple therapy, there are no studies investigating the cost-effectiveness of individual SITTs versus other SITTs. This study assessed the cost-effectiveness of SITT with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus other SITTs for the treatment of COPD from a UK National Health Service perspective.Patients and Methods: The validated GALAXY-COPD model was populated with patient baseline characteristics from the IMPACT study and treatment effect data from a network meta-analysis, which compared FF/UMEC/VI with budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FOR; both 320 μg and 160 μg dosing; BUD320 and BUD160, respectively) and beclometasone dipropionate/formoterol fumarate/glycopyrrolate (BDP/FOR/GLY). UK healthcare resource unit and drug costs (Great British Pound, 2022) were applied, with costs and outcomes (except life years [LYs]) discounted at 3.5% annually. The base case was probabilistic (5000 iterations) with a lifetime horizon.Results: FF/UMEC/VI provided an additional 0.620 (95% range: 0.255, 1.025) LYs and 0.283 (0.080, 0.501) quality-adjusted LYs (QALYs) with a cost saving of £ 1620 (£ 158, £ 3243) versus BUD320/GLY/FOR, an additional 0.627 (0.261, 1.053) LYs and 0.309 (0.097, 0.533) QALYs at a cost saving of £ 1721 (£ 261, £ 3345) versus BUD160/GLY/FOR, and an additional 0.328 (0.063, 0.654) LYs and 0.230 (0.035, 0.437) QALYs at a cost saving of £ 1221 (−£ 541, £ 2796) versus BDP/FOR/GLY. FF/UMEC/VI was less costly and showed higher QALYs in 98.2%, 98.9%, and 93.6% of simulations versus BUD360/GLY/FOR, BUD160/GLY/FOR, and BDP/FOR/GLY, respectively. At a willingness-to-pay threshold of £ 20,000 per QALY, the probability of FF/UMEC/VI being cost-effective was 99.9%, 100%, and 99.3% versus BUD320/GLY/FOR, BUD160/GLY/FOR, and BDP/FOR/GLY, respectively.Conclusion: Based on this analysis, FF/UMEC/VI is a dominant (improved outcomes with cost savings) treatment option compared with other SITTs for the treatment of patients with COPD in the UK.Keywords: chronic obstructive pulmonary disease, cost-effectiveness, fluticasone furoate/umeclidinium/vilanterol, GALAXY model, probabilistic |
| format | Article |
| id | doaj-art-88b5b0fbdf554bcf88b46583f55b3b1d |
| institution | Kabale University |
| issn | 1178-2005 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj-art-88b5b0fbdf554bcf88b46583f55b3b1d2025-08-20T03:39:41ZengDove Medical PressInternational Journal of COPD1178-20052025-08-01Volume 20Issue 127272743105531Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UKCai R0Martin AA1Ge YRisebrough NA2Haeussler K3Compton C4Halpin DM5Ismaila AS6HEORValue Evidence and OutcomesICON Health Economics and EpidemiologyHealth Economics and Outcomes ResearchGlobal Medical AffairsUniversity of Exeter Medical School, College of Medicine and HealthValue Evidence and OutcomesRui Cai,1 Alan A Martin,2 Yuchen Ge,3 Nancy A Risebrough,3 Katrin Haeussler,4 Christopher Compton,5 David MG Halpin,6 Afisi S Ismaila7,8 1ICON Health Economics, ICON plc, Amsterdam, the Netherlands; 2Value Evidence and Outcomes, GSK, London, UK; 3ICON Health Economics, ICON plc, Toronto, ON, Canada; 4ICON Health Economics, ICON plc, Munich, Germany; 5Global Medical, GSK, London, UK; 6University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK; 7Value Evidence and Outcomes, GSK, Collegeville, PA, USA; 8Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence: Afisi S Ismaila, Value Evidence and Outcomes, GSK, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA, Tel +19193158229, Email afisi.s.ismaila@gsk.comPurpose: Chronic obstructive pulmonary disease (COPD) is associated with a substantial economic burden in the UK. Although previous analyses have compared the cost-effectiveness of single-inhaler triple therapy (SITT) versus dual therapy or multiple-inhaler triple therapy, there are no studies investigating the cost-effectiveness of individual SITTs versus other SITTs. This study assessed the cost-effectiveness of SITT with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus other SITTs for the treatment of COPD from a UK National Health Service perspective.Patients and Methods: The validated GALAXY-COPD model was populated with patient baseline characteristics from the IMPACT study and treatment effect data from a network meta-analysis, which compared FF/UMEC/VI with budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FOR; both 320 μg and 160 μg dosing; BUD320 and BUD160, respectively) and beclometasone dipropionate/formoterol fumarate/glycopyrrolate (BDP/FOR/GLY). UK healthcare resource unit and drug costs (Great British Pound, 2022) were applied, with costs and outcomes (except life years [LYs]) discounted at 3.5% annually. The base case was probabilistic (5000 iterations) with a lifetime horizon.Results: FF/UMEC/VI provided an additional 0.620 (95% range: 0.255, 1.025) LYs and 0.283 (0.080, 0.501) quality-adjusted LYs (QALYs) with a cost saving of £ 1620 (£ 158, £ 3243) versus BUD320/GLY/FOR, an additional 0.627 (0.261, 1.053) LYs and 0.309 (0.097, 0.533) QALYs at a cost saving of £ 1721 (£ 261, £ 3345) versus BUD160/GLY/FOR, and an additional 0.328 (0.063, 0.654) LYs and 0.230 (0.035, 0.437) QALYs at a cost saving of £ 1221 (−£ 541, £ 2796) versus BDP/FOR/GLY. FF/UMEC/VI was less costly and showed higher QALYs in 98.2%, 98.9%, and 93.6% of simulations versus BUD360/GLY/FOR, BUD160/GLY/FOR, and BDP/FOR/GLY, respectively. At a willingness-to-pay threshold of £ 20,000 per QALY, the probability of FF/UMEC/VI being cost-effective was 99.9%, 100%, and 99.3% versus BUD320/GLY/FOR, BUD160/GLY/FOR, and BDP/FOR/GLY, respectively.Conclusion: Based on this analysis, FF/UMEC/VI is a dominant (improved outcomes with cost savings) treatment option compared with other SITTs for the treatment of patients with COPD in the UK.Keywords: chronic obstructive pulmonary disease, cost-effectiveness, fluticasone furoate/umeclidinium/vilanterol, GALAXY model, probabilistichttps://www.dovepress.com/economic-analysis-of-new-single-inhaler-triple-therapies-in-patients-w-peer-reviewed-fulltext-article-COPDChronic obstructive pulmonary diseasecost-effectivenessfluticasone furoate/umeclidinium/vilanterolGALAXY modelprobabilistic. |
| spellingShingle | Cai R Martin AA Ge Y Risebrough NA Haeussler K Compton C Halpin DM Ismaila AS Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK International Journal of COPD Chronic obstructive pulmonary disease cost-effectiveness fluticasone furoate/umeclidinium/vilanterol GALAXY model probabilistic. |
| title | Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK |
| title_full | Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK |
| title_fullStr | Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK |
| title_full_unstemmed | Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK |
| title_short | Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK |
| title_sort | economic analysis of new single inhaler triple therapies in patients with copd in the uk |
| topic | Chronic obstructive pulmonary disease cost-effectiveness fluticasone furoate/umeclidinium/vilanterol GALAXY model probabilistic. |
| url | https://www.dovepress.com/economic-analysis-of-new-single-inhaler-triple-therapies-in-patients-w-peer-reviewed-fulltext-article-COPD |
| work_keys_str_mv | AT cair economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk AT martinaa economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk AT gey economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk AT risebroughna economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk AT haeusslerk economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk AT comptonc economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk AT halpindm economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk AT ismailaas economicanalysisofnewsingleinhalertripletherapiesinpatientswithcopdintheuk |